Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Expression of Chemokine Receptors on Th1/Th2 Cd4+ Lymphocytes in Patients With Multiple Sclerosis Pubmed



Andalib A1 ; Doulabi H1 ; Najafi M2 ; Tazhibi M3 ; Rezaie A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Immunology Department, Isfahan University of MedicalSciences, Isfahan, Iran
  2. 2. Neurology Department, Isfahan Medical School, Isfahan University of MedicalSciences, Isfahan, Iran
  3. 3. Biostatic Department, Isfahan University of MedicalSciences, Isfahan, Iran

Source: Iranian Journal of Immunology Published:2011


Abstract

Background: Th1 cells preferentially express CXCR3, CCR5 and CCR6, while CCR3 and CCR4 are predominantly expressed by Th2 cell subsets. Multiple Sclerosis (MS) is a Th1 cell-dependant chronic inflammatory disease of the central nervous system, and immunomudolatory cytokines could alter the chemokine expression pattern of these lymphocyte subsets. Objective: This study was performed to measure chemokine receptor expression on CD4 T cells for evaluation of Th1/Th2 dominantly in IFN-β treated patients. Methods: flowcytometry was used to detect chemokine receptor expression on CD4 T cell population in PBMCs obtained from MS and healthy control groups. Twenty six MS patients participated in this study before and after IFN-β therapy and the same number of healthy individuals were included. Results: The percentage of lymphocytes was 41.28% ± 10.30 in the blood of MS group compared with 36.88% ± 5.51% in the control group (p=0.017). The CD4+CXCR3+ cells were 18.86% ± 8.46% in healthy group, 30.78% ± 9.8% in pre-treated MS patients and 21.06% ± 9.23% in post-treated group (p<0.001). The CD4+CCR4+ cell subsets were 27.35% ± 10.15% in healthy group; 28.17% ± 8.9% in pre-treated group and 34.20% ± 8.96% in the post- IFN-β treatment group. The subset of CD4+CCR4+ was found to be dominant after IFN- β therapy in comparison with the control group (p<0.001). CD4+CCR5+ percentage was 1.24% ± 0.92% in the healthy people, 1.23% ± 0.71% in the MS patients and 0.76% ± 0.49% in post-treatment status (p=0.003). CD4+CCR3+ cell subsets were 0.62% ± 0.67% in control group, 0.28% ± 0.26% in the MS patients (p=0.022) and 0.39% ± 0.54% in IFN-β treated patients (p=0.334). An association was found for CXCR3 expression in pre- and post- treatment status (r=0.840, p<0.001) as well as for CCR4+ expression (r=0.712, p<0.001) in the same groups. The Th1 response was dominant in pre-treatment states, and then it shifted to a Th2 dominant state after IFN-β treatment. Conclusion: We suggest that the chemokine receptor expression of Th1/Th2 cell subsets could be used for monitoring and the evaluation of the MS disease status.
Related Docs
View other Related Docs
1. Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges, CNS and Neurological Disorders - Drug Targets (2018)
2. Comparison of Follicular T Helper Cells, Monocytes, and T Cells Priming Between Newly Diagnosed and Rituximab-Treated Ms Patients and Healthy Controls, Research in Pharmaceutical Sciences (2022)
3. The Expression of Th1- and Th2-Related Chemokine Receptors in Women With Recurrent Miscarriage: The Impact of Lymphocyte Immunotherapy, American Journal of Reproductive Immunology (2010)
4. Toll Like Receptor 2 and 4 Expression in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients, Iranian Journal of Immunology (2014)
5. Therapeutic Plasma Exchange May Adjust Il-6 and Tgf-Β Signals in Relapsed Ms Patients Peripheral Blood, Journal of Clinical Apheresis (2020)
6. Antibodies to Interferon Beta in Patients With Multiple Sclerosis Receiving Cinnovex, Rebif, and Betaferon, Journal of Korean Medical Science (2013)
7. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
8. Assessing Cell Cycle of Human T Lymphocytes Activated by Anti-Cd3 and Anti-Cd28 Monoclonal Antibodies Using Flow Cytometry in Vitro, Journal of Isfahan Medical School (2012)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (16)
Masoud Etemadifar (15)
Other Related Docs
9. Decreased Serum Levels of Interleukin-35 Among Multiple Sclerosis Patients May Be Related to Disease Progression, Journal of Biological Regulators and Homeostatic Agents (2018)
10. The Immunomodulatory Aspect of Quercetin Penta Acetate on Th17 Cells Proliferation and Gene Expression in Multiple Sclerosis, Cell Journal (2023)
11. Endogenous Expression of the Atypical Chemokine Receptor Ccx-Ckr (Ccrl1) Gene in Human Embryonic Kidney (Hek 293) Cells, Molecular and Cellular Biochemistry (2016)
12. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
13. Lncrnas Associated With Multiple Sclerosis Expressed in the Th1 Cell Lineage, Journal of Cellular Physiology (2019)
14. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
15. Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients, Inflammation (2019)
16. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
17. Elevated Csf Concentration of Ccl3 and Ccl4 in Relapsing Remitting Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
18. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
19. Biased Treg/Th17 Balance Away From Regulatory Toward Inflammatory Phenotype in Relapsed Multiple Sclerosis and Its Correlation With Severity of Symptoms, Journal of Neuroimmunology (2013)
20. The Effect of Plasma Exchange on the Expression of Foxp3 and Rorc2 in Relapsed Multiple Sclerosis Patients, Iranian Journal of Immunology (2015)
21. The Frequencies of Peripheral Blood Cd5+Cd19+ B Cells, Cd3−Cd16+Cd56+ Nk, and Cd3+Cd56+ Nkt Cells and Serum Interleukin-10 in Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder, Allergy, Asthma and Clinical Immunology (2022)
22. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)
23. Cerebrospinal Fluid and Serum Markers of Inflammation in Patients With Multiple Sclerosis, Advances in Neuroimmune Biology (2017)
24. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
25. Increased Expression of Lymphocyte Activation Gene-3 by Regulatory T Cells in Multiple Sclerosis Patients With Fingolimod Treatment; [Multiple Sikleroz Hastalarinda Fingolimod Tedavisi Sonucu Duzenleyici T Hucrelerinde Lenfosit Aktivasyon Gen-3 Ekspresyonunda Artis], Turkish Journal of Immunology (2019)
26. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
27. Cd24 Gene Allele Variation Is Not Associated With Oligoclonal Igg Bands and Igg Index of Multiple Sclerosis Patients, NeuroImmunoModulation (2012)
28. In Vitro Selective Depletion of Cd4+Cd25+ Regulatory T-Cells From Pbmc Using Anti-Tac-Sap, Journal of Immunotoxicology (2012)
29. Evaluating the Effects of Epigallocatechin-3-Gallate on Hif-1Α Protein and Rorc Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Multiple Sclerosis, Basic and Clinical Neuroscience (2021)
30. Evaluation of Soluble Human Leukocyte Antigen-G (Shla-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2015)
31. Apamin As a Bbb Shuttle and Its Effects on T Cell Population During the Experimental Autoimmune Encephalomyelitis-Induced Model of Multiple Sclerosis, Neurotoxicity Research (2021)
32. The Role of Nk and Nkt Cells in the Pathogenesis and Improvement of Multiple Sclerosis Following Disease-Modifying Therapies, Health Science Reports (2022)
33. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
34. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
35. Cxcl-10: A New Candidate for Melanoma Therapy?, Cellular Oncology (2020)
36. Evaluation of Lymphocyte Activation Gene3 (Lag-3) on Regulatory T Cells in Patients With Multiple Sclerosis by Intervention Effect of Fingolimod, Journal of Isfahan Medical School (2016)
37. The Role of Immune Regulatory Molecules in Multiple Sclerosis, Journal of Neuroimmunology (2019)
38. Correlation of Midkine Serum Level With Pro- and Anti-Inflamatory Cytokines in Multiple Sclerosis, Iranian Journal of Immunology (2014)
39. Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in Ms Patients: A Double-Blind Placebo-Controlled Clinical Trial, International Immunopharmacology (2021)
40. Tnf-Alpha Production by Peripheral Blood Monocytes in Multiple Sclerosis Patients and Healthy Controls, Immunological Investigations (2015)
41. Il-22 Produced by T Helper Cell 22 As a New Player in the Pathogenesis of Immune Thrombocytopenia, Endocrine, Metabolic and Immune Disorders - Drug Targets (2015)
42. The +4259A>C Polymorphism of Tim-3 But Not -1637C>T Polymorphism of Tim-1 Is Associated With Multiple Sclerosis in Isfahan Population, Multiple Sclerosis and Related Disorders (2017)
43. Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients, Cell Journal (2016)
44. The Effect of Silymarin on the Expression of Chemokine Receptors in T Helper 1 (Th1) Cells, Journal of Isfahan Medical School (2014)
45. Immunophenotypic Characterization of Peripheral Blood T-Lymphocytes and Their Subpopulations in Tuberculosis Patients Before and After Treatments, Iranian Journal of Allergy, Asthma and Immunology (2005)
46. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
47. Evaluation of the Effect of Gm-Csf Blocking on the Phenotype and Function of Human Monocytes, Scientific Reports (2020)
48. Association of Interleukin-1 Gene Cluster Polymorphisms and Haplotypes With Multiple Sclerosis in an Iranian Population, Journal of Neuroimmunology (2015)
49. Designing and Characterization of Tregitope-Based Multi-Epitope Vaccine Against Multiple Sclerosis: An Immunoinformatic Approach, Current Drug Safety (2023)
50. Forkhead Box Protein 3 and Regulatory T Cells in Cluster of Differentiation 4 and 8 T Cell Subsets in Peripheral Blood of Patients With Breast Cancer, Journal of Isfahan Medical School (2012)